Chemical Property of Vernakalant hydrochloride
Chemical Property:
- PSA：51.16000
- LogP:3.38060
- Storage Temp.:Hygroscopic, Refrigerator, under inert atmosphere
- Solubility.:DMSO (Slightly), Methanol (Slightly)
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:7
- Exact Mass:385.2019862
- Heavy Atom Count:26
- Complexity:394
- Purity/Quality:
-
97% *data from raw suppliers
VernakalantHydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:COC1=C(C=C(C=C1)CCOC2CCCCC2N3CCC(C3)O)OC.Cl
- Isomeric SMILES:COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC.Cl
- Recent ClinicalTrials:A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
- Recent EU Clinical Trials:A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation.
-
Uses
Treatment of patients with atrial fibrillation and atrial flutte. Vernakalant Hydrochloride is a novel, relatively atrial-selective antiarrhythmic drug that effectively and rapidly terminates atrial fibrillation (AF).
-
Clinical Use
Vernakalant is an investigational drug under regulatory review for the acute conversion of atrial
fibrillation. The drug was initially developed by Cardiome Pharma under the trade names Kynapid ?
and Brinavess ? and its intravenous formulation was further developed by Merck in April 2009. Like other class III antiarrhythmics, vernakalant blocks atrial potassium channels, thereby
prolonging repolarization. It differs from typical class III agents by blocking the cardiac
transient outward potassium current, with increased potency as the heart rate increases. It also slightly
blocks the hERG potassium channel, leading to a prolonged QT interval, which may theoretically
increase the risk of ventricular tachycardia.
